Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Lan, Beidi ^a   Hayama, Emiko ^a   Kawaguchi, Nanako ^a   Furutani, Yoshiyuki ^a   Nakanishi, Toshio ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; MESSENGER RNA; MONOCROTALINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; VALPROIC ACID; HISTONE DEACETYLASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; HYPOXIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; TREATMENT DURATION; WEIGHT GAIN; ANIMAL; BLOOD PRESSURE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; PATHOLOGY; PULMONARY ARTERY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HEMODYNAMICS; HISTONE DEACETYLASE INHIBITORS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; HYPOXIA; LUNG; MALE; MONOCROTALINE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; VALPROIC ACID;

EID: 84922166469     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117211     Document Type: Article

References (27)

1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, et al. (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573-1619. doi: 10.1016/j.jacc. 2009.01.004 PMID: 19389575
2. Sharma NL, Groselj B, Hamdy FC, Kiltie AE (2013) The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. BJU Int 111:537-542. doi: 10.1111/j.1464-410X.2012.11647.x PMID: 23551441
3. Ververis K, Hiong A, Karagiannis TC, Licciardi PV (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7:47-60. doi: 10.2147/BTT.S29965 PMID: 23459471
4. Brodie SA, Brandes JC (2014) Could valproic acid be an effective anticancer agent? The evidence so far. Expert Rev Anticancer Ther 14:1-4. doi: 10.1586/14737140.2014.863713 PMID: 24308682
5. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, et al. (2012) Histone deacetylation inhibition in pulmonary hypertension. Therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126:455-467. doi: 10.1161/CIRCULATIONAHA.112.103176 PMID: 22711276
6. Morimatsu Y, Sakashita N, Komohara Y, Ohnishi K, Masuda H, et al. (2012) Development and characterization of an animal model of severe pulmonary arterial hypertension. J Vasc Res 49:33-42. doi: 10. 1159/000329594 PMID: 21985792
7. Diebold I, Petry A, Hess J, Görlach A (2010) The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol Biol Cell 21:2087-2096. doi: 10.1091/mbc.E09-12-1003 PMID: 20427574
8. Rondelet B,Kerbaul F,Motte S, Van Beneden R, Remmelink M, et al. (2003) Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 107:1329-1335. PMID: 12628956
9. Nishimura T,Vaszar LT,Faul JL, Zhao G, Berry GJ, et al. (2003) Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108 (13):1640-1645. PMID: 12963647
10. Dahal BK,Kosanovic D,Pamarthi PK, Sydykov A, Lai YJ, et al. (2010) Therapeutic efficacy of azain-dole-1 in experimental pulmonary hypertension. Eur Respir I 36: 808-818. doi: 10.1183/09031936. 00140309 PMID: 20530035
11. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297:L1013-L1032. doi: 10.1152/ajplung.00217.2009 PMID: 19748998
12. Abe K,Toba M,Alzoubi A, Ito M, Fagan KA, et al. (2010) Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension. Circulation 121:2747-2754. doi: 10.1161/ CIRCULATIONAHA.109.927681 PMID: 20547927
13. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, et al. (1997) Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. AM J Pathol 151: 1019-1025. PMID: 9327735
14. Bush EW, McKinsey TA (2010) Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Cir Res 106:272-284.
15. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, et al. (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98:604-610. doi: 10.1038/sj.bjc.6604199 PMID: 18212746
16. Jurkin J, Zupkovitz G, Lagger S, Grausenburger R, Hagelkruys A, et al. (2011) Distinct and redundant functions of histone deacetylases associated HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 10:406-412. PMID: 21270520
17. Bolden JE, Pear MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784. PMID: 16955068
18. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741. PMID: 11473107
19. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978. PMID: 11742974
20. Cho YK, Eom GH, Kee HJ, Kim HS, Choi WY, et al. (2010) Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J 74:760-770. PMID: 20208383
21. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, et al. (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206-222. doi: 10.1016/j.ctrv.2007.11.003 PMID: 18226465
22. Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, et al. (2009) Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 297:996-1005.
23. Cao W, Bao C, Padalko E, Lowenstein CJ (2008) Acetylation of mitogen-activated protein kinase phos-phatase-1 inhibits Toll-like receptor signaling. J Exp Med 205:1491-1503. doi: 10.1084/jem.20071728 PMID: 18504304
24. Klamper L, Huang J, Swaby LA, Augenlicht L (2004) Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 279:30358-30368. PMID: 15123634
25. Calao M, Burny A, Quivy V, Dekoninck A, Van LC (2008) A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. Trends Biochem Sci 33:339-349. doi: 10.1016/j. tibs.2008.04.015 PMID: 18585916
26. Iyer A, Fenning A, Lim J, Le GT, Reid RC, et al. (2010) Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol 159(7):1408-1417. doi: 10.1111/j.1476-5381.2010.00637.x PMID: 20180942
27. Glenn DJ, Wang F, Chen S, Nishimoto M, Gardner DG (2009) Endothelin-stimulated human B-type natriuretic peptide gene expression is mediated by Yin Yang 1 in association with histone deacetylase 2. Hypertension 53: 549-555. doi: 10.1161/HYPERTENSIONAHA.108.125088 PMID: 19139378